AG
RCUS icon

Aperio Group’s Arcus Biosciences RCUS Stock Holding History

Aperio Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$231K Buy
+8,909
New +$216K ﹤0.01% 2269
2019
Q3 		– Sell
-3,999
Closed -$32K – 2659
2019
Q2 		$32K Buy
+3,999
New +$40K ﹤0.01% 2615

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aperio Group's RCUS Position: Q4 2020 in Review

Aperio Group opened a new position in Arcus Biosciences (RCUS) in Q4 2020: 8,909 shares worth $231K. The stake represents ﹤0.01% of the portfolio and ranks #2269 among its holdings. This is a return to the name: Aperio Group previously reported a position in RCUS as recently as Q2 2019.

Aperio Group first reported a position in RCUS in Q2 2019 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold RCUS as of Q4 2020.

  • Aperio Group held 8,909 shares of Arcus Biosciences worth $231K as of Q4 2020.
  • Arcus Biosciences was a new Aperio Group position in Q4 2020.
  • Arcus Biosciences made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2269 holding.
  • Aperio Group first reported a position in Arcus Biosciences in Q2 2019 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.